Femtech startup Ipremom secures €15 million seed round to develop early detection technology for pregnancy complications, signaling strong investor appetite for women's health innovation in Europe
Executive summary: Ipremom, a European femtech startup focused on early detection of pregnancy complications, has raised a €15 million seed round as reported by Sifted on September 2, 2026. The sizable seed round signals robust investor confidence in maternal health technology and could catalyze further funding for femtech ventures addressing pregnancy-related risks, a market with high unmet clinical need.
Who is involved: Ipremom (femtech startup); undisclosed investors; Sifted (reporting outlet).
Likely next: Ipremom will likely allocate capital toward clinical trials, regulatory clearance (CE marking under MDR), and team expansion; subsequent Series A fundraising expected within 12–18 months if milestones are met.
Ipremom's €15 million seed funding represents one of the largest early-stage raises in European femtech this year, underscoring growing venture capital interest in maternal health technology. The round highlights a shift toward preventive diagnostics in obstetrics, a market historically underserved by digital health investment. The capital will likely accelerate clinical validation and regulatory pathways for the company's detection platform.
Timeline
- — Exclusive: Femtech Ipremom raises €15m seed for early detection of pregnancy complications (Sifted — EU startups)
Analysis — what this means
Likely next events
- Ipremom initiates pivotal clinical study for CE marking under EU MDR 2017/745 by Q1 2027
- Potential Series A raise targeting €40–60m contingent on clinical data readout
- EU AI Act high-risk classification assessment for diagnostic algorithm by mid-2027
Sectors affected
- femtech
- maternal health diagnostics
- digital health
- medical devices
Regulatory implications
- EU MDR 2017/745 Class IIa/IIb classification likely; requires notified body oversight and clinical evaluation
- EU AI Act may apply if algorithm drives clinical decisions; conformity assessment required before market placement
- GDPR compliance for sensitive pregnancy health data processing mandatory
Historical parallels
- Elvie's £70m Series C (2021) demonstrated femtech scalability beyond consumer hardware
- Flo Health's $50m Series B (2022) showed investor appetite for women's health platforms
- Ava Women's FDA clearance (2019) established regulatory precedent for fertility tracking wearables
Key entities
Sources
- Exclusive: Femtech Ipremom raises €15m seed for early detection of pregnancy complications — Sifted — EU startups